ABSTRACT
We perform a counterfactual time series analysis of 2020 weekly total mortality data reported from towns in Italy, with data from the previous five years as control. We find an excess mortality that is correlated in time with the COVID-19 reported death rate time series, the latter lagging in time by about one week. Relative to the reported deaths by COVID-19, the overall excess mortality is significantly higher for many of the regions in Italy, and its age distribution is skewed towards people above 80 years of age. We estimate that the number of COVID-19 deaths in Italy is 47,000 ± 2000 as of April 11 2020, more than a factor of 2 higher than the official number. We estimate the Population Fatality Rate (PFR), defined as the ratio of COVID-19 related deaths to the total population. It has reached 0.2% in the most affected region of Lombardia as of April 11, and 0.4% in the most affected province of Bergamo, which is also a lower bound to the Infection Fatality Rate (IFR). We estimate PFR as a function of age, finding a steep age dependence: in Lombardia (Bergamo province) 0.5% (1.1%) of total population in age group 70-79 died, 1.3% (3%) in age group 80-89, and 3% (7%) in the age group above 90. We combine this with the IFR estimate from the Princess Diamond cruise ship for ages above 70 to estimate the age dependent IFR which range from below 0.1% for ages below 50 years to 15% for ages above 90 years, with an overall IFR of 1.1% for Lombardia. Combining with the PFR, we estimate the infection rates (IR) of regions in Italy which peaks in Lombardia at 21% (10%-37%, 95% c.l.), and for provinces in Bergamo at 48% (24%-85%, 95% c.l.), corresponding to 2 Million and 0.5 Million infected people, respectively. Our code and data is available at , and will be updated as situation evolves.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We get the data from Istat - https://www.istat.it/it/files//2020/03/comuni-settimana.zip and make public, both the raw and clean datasets used.